Azorin J-M
SHU Psychiatrie adultes-Pavillon Solaris, Hôpital Sainte-Marguerite, 13274 Marseille, Cedex 09, France.
Encephale. 2013 Sep;39 Suppl 2:S121-3. doi: 10.1016/S0013-7006(13)70107-6.
The current review raises the question of the place of long-acting injectable (LAI) atypical antipsychotics for the treatment of first-episode schizophrenia in current and future guidelines. After exposing the different points of view adopted in the former, the author presents the clinical trials conducted with LAI atypicals in this indication, as well as the surveys related to psychiatrists'opinion regarding the use of these drugs in early schizophrenia. Pros and cons of this therapeutic option are discussed and suggestions are made for further guidelines.
当前的综述提出了长效注射用（LAI）非典型抗精神病药物在当前及未来指南中用于治疗首发精神分裂症的地位问题。在阐述了之前采用的不同观点后，作者介绍了针对该适应症使用LAI非典型药物开展的临床试验，以及与精神科医生关于在早期精神分裂症中使用这些药物的观点相关的调查。讨论了这一治疗选择的利弊，并对进一步的指南提出了建议。
